Data Supplement

• Supplemental Data -

  Supplemental Table S1. Lot information for freshly isolated human hepatocytes used in this study.

  Supplemental Table S2. Settings for midazolam and caffeine PBPK simulations.

  Supplemental Table S3. Compound specific parameters for NN1177 for PBPK model.

  Supplemental Table S4. Cooperstown 5+1 index substrates (“DDI cocktail”).

  Supplemental Table S5. Mean in vitro CYP enzyme mRNA and activity following NNC9204-1177 exposure.

  Supplemental Table S6. Mean fold-increase in vitro CYP enzyme mRNA and activity for controls.

  Supplemental Table S7. AUCinf metabolite/parent ratios before and after NN1177 exposure.

  Supplemental Table S8. Change in subject body weight during trial.

  Supplemental Figure S1. Observed and predicted NN1177 PK on day 70.

  Supplemental Figure S2. Effect of NN1177 on Cooperstown 5+1 metabolite profiles in clinic.

  Supplemental Figure S3. NN1177 plasma concentration over the course of the trial.